OABI NASDAQ
Credit Risk of going bust: lower than 56% of companies Debt: 2.7% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.02 (down 99.6%), OmniAb, Inc. would be worth roughly what it owes.
Total debt $18.9M against a stock market value of $670.2M.
Distance to default 5.73 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $9.5M (short-term plus half of long-term), stock volatility 71.9%; Altman Z'' 7.26. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
EmeryVille, CA 94608
US
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Nwachuku Amechi Ekek | A-Award | 800,000 | $1.98 | 2026-08-01 |
| Nwachuku Amechi Ekek | 0 | — | 2026-07-13 | |
| Crouse Steven C. | M-Exempt | 20,000 | — | 2026-06-17 |
| Crouse Steven C. | M-Exempt | 20,000 | — | 2026-06-17 |
| Crouse Steven C. | A-Award | 20,000 | — | 2026-06-17 |